388 related articles for article (PubMed ID: 28581694)
1. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
[TBL] [Abstract][Full Text] [Related]
2. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
[TBL] [Abstract][Full Text] [Related]
3. Type 2N von Willebrand disease: Characterization and diagnostic difficulties.
Casonato A; Galletta E; Sarolo L; Daidone V
Haemophilia; 2018 Jan; 24(1):134-140. PubMed ID: 29115006
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
5. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
Favaloro EJ; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():679-691. PubMed ID: 37204745
[TBL] [Abstract][Full Text] [Related]
6. A novel mouse model of type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human type 2N VWD.
Shi Q; Fahs SA; Mattson JG; Yu H; Perry CL; Morateck PA; Schroeder JA; Rapten J; Weiler H; Montgomery RR
Blood Adv; 2022 May; 6(9):2778-2790. PubMed ID: 35015821
[TBL] [Abstract][Full Text] [Related]
7. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
[TBL] [Abstract][Full Text] [Related]
8. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
Ryu JH; Bauer KA; Schulman S
J Thromb Haemost; 2023 Dec; 21(12):3508-3510. PubMed ID: 37734716
[TBL] [Abstract][Full Text] [Related]
9. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand disease type 2N: An update.
Seidizadeh O; Peyvandi F; Mannucci PM
J Thromb Haemost; 2021 Apr; 19(4):909-916. PubMed ID: 33497541
[TBL] [Abstract][Full Text] [Related]
11. The Lesson Learned from the New c.2547-1G > T Mutation Combined with p.R854Q: When a Type 2N Mutation Reveals a Quantitative von Willebrand Factor Defect.
Casonato A; Cozzi MR; Ferrari S; Rubin B; Gianesello L; De Marco L; Daidone V
Thromb Haemost; 2022 Sep; 122(9):1479-1485. PubMed ID: 35189660
[TBL] [Abstract][Full Text] [Related]
12. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.
Chauhan AK; Kisucka J; Lamb CB; Bergmeier W; Wagner DD
Blood; 2007 Mar; 109(6):2424-9. PubMed ID: 17119108
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
[TBL] [Abstract][Full Text] [Related]
14. Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Haemophilia; 2021 Mar; 27(2):e194-e203. PubMed ID: 33555083
[TBL] [Abstract][Full Text] [Related]
15. Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment?
Seidi Zadeh O; Ahmadinejad M; Amoohossein B; Homayoun S
Blood Coagul Fibrinolysis; 2020 Sep; 31(6):382-386. PubMed ID: 32815913
[TBL] [Abstract][Full Text] [Related]
16. Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD).
Mohammed S; Favaloro EJ
Methods Mol Biol; 2017; 1646():461-472. PubMed ID: 28804848
[TBL] [Abstract][Full Text] [Related]
17. The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.
Swystun LL; Notley C; Georgescu I; Lai JD; Nesbitt K; James PD; Lillicrap D
J Thromb Haemost; 2019 Apr; 17(4):681-694. PubMed ID: 30740857
[TBL] [Abstract][Full Text] [Related]
18. The genetic basis of von Willebrand disease.
Goodeve AC
Blood Rev; 2010 May; 24(3):123-34. PubMed ID: 20409624
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.
Casonato A; Pontara E; Zerbinati P; Zucchetto A; Girolami A
Am J Clin Pathol; 1998 Mar; 109(3):347-52. PubMed ID: 9495210
[TBL] [Abstract][Full Text] [Related]
20. The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF-FVIII clearance in thrombosis and hemostasis.
Swystun LL; Michels A; Lillicrap D
J Thromb Haemost; 2023 Aug; 21(8):2007-2019. PubMed ID: 37085036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
